Clinical trials: Plasmodium Vivax Malaria
Plasmodium Vivax Malaria
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the…
- Trial name
- SEADOT (NCT04704999)
- Testing
- Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg
- Where
- 6 sites in Cambodia, Indonesia and 3 more
- Volunteers
- 820 people
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute
Plasmodium Vivax Malaria, Vivax Malaria
Tafenoquine Drug Levels in Small Children
This study is an open label, single arm, pharmacokinetic trial. A total of 20 participants (children ≤12kg and >28 days old) will be enrolled.
- Trial name
- TQP (NCT07835321)
- Testing
- Chloroquine, Tafenoquine
- Where
- 2 sites in Thailand, Vietnam
- Volunteers
- 20 people
- Sponsor
- University of Oxford
Malaria Vivax, Malaria Falciparum
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria…
- Conditions
- Malaria Vivax, Malaria Falciparum, Plasmodium Vivax, Plasmodium Falciparum
- Trial name
- PvSTATEM (NCT06923592)
- Testing
- PvSeroTAT, Control
- Where
- 2 sites in Ethiopia, Madagascar
- Volunteers
- 19,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Vivax Malaria, Malaria
FocaL Mass Drug Administration for Vivax Malaria Elimination
FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru.
- Trial name
- FLAME (NCT05690841)
- Testing
- Focal Mass Drug Administration (fMDA)
- Where
- Peru
- Volunteers
- 7,530 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
This study assesses the effectiveness and feasibility of enhanced reactive case detection (RACD) targeting high-risk villages and forest workers for reducing Plasmodium falciparum and Plasmodium vivax transmission in southern Lao…
- Trial name
- COMBAT (NCT04416945)
- Testing
- Household Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up
- Where
- Laos
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
This study assesses the effectiveness of reactive focal mass drug administration (rfMDA), targeting both village and forest working populations, compared to control for reducing the health promotion hospital-level (sub-district)…
- Trial name
- COMBAT (NCT05052502)
- Testing
- Case Management and Follow-up, Reactive focal mass drug administration (rfMDA)
- Where
- Thailand
- Volunteers
- 14,977 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Vivax Infection
Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults
This study is a human challenge study to assess the minimum infective mosquito bite dose in a controlled human malaria Infection (via P. vivax sporozites) in healthy volunteers. The results will inform the development of a P.
- Trial name
- MIST4 (NCT07257965)
- Testing
- Mosquito bite (1 or 2 or 3)
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Infection, Malaria Vaccine
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
This project is the third part of a 5-year research program entitled "Malaria Infection Studies in Thailand (MIST)" and known as MIST3.
- Trial name
- MIST3 (NCT05380388)
- Testing
- Malaria Vaccine, HBV vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria, Plasmodium Vivax Infection
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
This clinical study will evaluate an investigational malaria vaccine called PvCS/Montanide ISA-51 to determine whether it is safe and whether it can protect adults from infection with Plasmodium vivax, one of the main parasites…
- Conditions
- Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention
- Trial name
- PvCS/M51 (NCT07373301)
- Testing
- PvCS/Montanide ISA-51 VG Vaccine
- Where
- Colombia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria, Malaria, Vivax
Vivax Elimination With Tafenoquine (VET) Study
Theoretically, so long as there is a sink-source for malaria, transmission could be sustained at very low level (even at sub-microscopic oscillation) and reintroduce malaria either as sporadic cases or as resurgent outbreak.
- Conditions
- Malaria, Malaria, Vivax, Plasmodium Vivax, Plasmodium Vivax Malaria
- Trial name
- VET (NCT06575647)
- Testing
- Tafenoquine
- Where
- Thailand
- Volunteers
- 1,242 people
- Sponsor
- Shoklo Malaria Research Unit
Malaria, Plasmodium Vivax Infection
Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria
This study aimed to compare platelet count patterns in patients infected with either Plasmodium vivax or Plasmodium falciparum, the two most common malaria species in Pakistan.
- Conditions
- Malaria, Plasmodium Vivax Infection, Plasmodium Falciparum Infection, Thrombocytopenia
- Trial name
- NCT07122232
- Where
- Pakistan
- Volunteers
- 177 people
- Sponsor
- Rafiullah Hotak
Malaria, Malaria, Vivax
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of illness.
- Conditions
- Malaria, Malaria, Vivax, Plasmodium Vivax Malaria
- Trial name
- ACTQ (NCT05788094)
- Testing
- Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
- Where
- Thailand
- Volunteers
- 606 people
- Sponsor
- Shoklo Malaria Research Unit
Vivax Malaria, Plasmodium Vivax
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
Health care facility based, randomized, controlled, open label, superiority trial with 3 arms
- Conditions
- Vivax Malaria, Plasmodium Vivax, Malaria, Vivax, Malaria Relapse
- Trial name
- EFFORT (NCT04411836)
- Testing
- Tafenoquine, Primaquine
- Where
- 6 sites in Cambodia, Ethiopia and 2 more
- Volunteers
- 960 people
- Sponsor
- Menzies School of Health Research
Malaria, Mass Drug Administration
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Plasmodium vivax has become the predominant species in the Greater Mekong Subregion and is a major challenge for regional malaria elimination.
- Conditions
- Malaria, Mass Drug Administration, Myanmar, Plasmodium Vivax
- Trial name
- NCT06392152
- Testing
- Focal Mass Drug Administration with Primaquine
- Where
- Burma
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- Pyae Linn Aung
Plasmodium Vivax
Phenotyping and Genotyping of Duffy Antigen
Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control.
- Trial name
- DARC (NCT05527119)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Malaria,Falciparum, Malaria, Vivax
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua
Comparing the efficacy of the combination treatment of bitter melon fruit extract (Momordica charantia) with primaquine (MC+PQ) against the combination of dihydroartemisinin + piperaquine + primaquine (DHP+PQ) on patients with…
- Conditions
- Malaria,Falciparum, Malaria, Vivax, Malaria, Infections
- Trial name
- MCMPFPB (NCT06036030)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Plasmodium Falciparum, Plasmodium Vivax
The Malaria Heart Disease Study
The Malaria Heart Disease Study is a prospective longitudinal cohort study of a random sample of approximately 1200 individuals from the state of Acre in Brazil.
- Conditions
- Plasmodium Falciparum, Plasmodium Vivax, Heart Diseases, Cardiovascular Diseases
- Trial name
- NCT04445103
- Testing
- Assessment of cardiac function
- Where
- Brazil
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Plasmodium Falciparum and Plasmodium Vivax
Malaria Genetic Surveillance
This study is to determine the prevalence and geographical distribution of antimalarial drug resistance-linked genetic mutations in clinical P. falciparum and/or P.Vivax infection in the Greater Mekong Subregion
- Trial name
- NCT03384498
- Where
- 3 sites in Cambodia, Laos and 1 more
- Volunteers
- 30,000 people
- Sponsor
- University of Oxford
Plasmodium Vivax
P.Vivax Treatment Trial
This study aims to determine whether a 14 day course of 0.5 mg/kg/day primaquine can eliminate subclinical P. vivax infections detected by high volume ultra-sensitive PCR (uPCR).
- Trial name
- Lao Pv (NCT02802813)
- Testing
- Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)
- Where
- Laos
- Volunteers
- 41 people
- Sponsor
- University of Oxford